言語を選択

Complement C1s

Complement C1s 詳細

英語名	Complement C1s	市販薬剤の数	4
治験薬の数	5	ターゲットの別称	EC:3.4.21.42，EC 3.4.21，C1 esterase，Complement component 1 subcomponent s，C1S，Complement C1s，Complement Component 1， S Subcomponent，Basic Proline-Rich Peptide IB-1，Complement C1s Subcomponent，EC 3.4.21.42，EDSPD2
研究＆開発段階	Approved

英語名	Complement C1s
ターゲットの別称	EC:3.4.21.42，EC 3.4.21，C1 esterase，Complement component 1 subcomponent s，C1S，Complement C1s，Complement Component 1， S Subcomponent，Basic Proline-Rich Peptide IB-1，Complement C1s Subcomponent，EC 3.4.21.42，EDSPD2
市販薬剤の数	4
治験薬の数	5
研究＆開発段階	Approved

Complement C1s 製品リスト

属性
Protein (2)
製品ライブラリ
オンライン (2)
種
Human (1)Cynomolgus (1)
タグ
His Tag (2)
マーカー
Unconjugated (2)

製品番号	種	発現システム	製品説明	タンパク質の構造	純度	特性
COS-H52H3	Human	HEK293	Human Complement C1s Protein, His Tag, low endotoxin (MALS verified)
COS-C52H3	Cynomolgus	HEK293	Cynomolgus Complement C1s Protein, His Tag (MALS verified)

総数量2

Complement C1sバックグランド

This gene encodes a serine protease, which is a major constituent of the human complement subcomponent C1. C1s associates with two other complement components C1r and C1q in order to yield the first component of the serum complement system. Defects in this gene are the cause of selective C1s deficiency.

Complement C1s分子の別称

EDSPD2

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Complement-C1 inhibitor protein (Octapharma)		Phase 3 Clinical	Octapharma	Angioedemas, Hereditary	詳細
Riliprubart	BIVV-020; SAR-445088; TNT-020	Phase 3 Clinical	True North Therapeutics	Anemia, Hemolytic, Autoimmune; Graft Rejection; Nervous System Diseases; Polyradiculoneuropathy; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Purpura, Thrombocytopenic, Idiopathic	詳細
C1 esterase inhibitor (Boya Bio-Pharmaceutical)		Phase 3 Clinical	Boya Bio-Pharmaceutical Group Co Ltd	Angioedemas, Hereditary	詳細
Claseprubart	DNTH103; DNTH-103	Phase 3 Clinical	Dianthus Therapeutics Inc	Autoimmune Diseases; Motor Neuron Disease; Multifocal Motor Neuropathy; Myasthenia Gravis; Nervous System Diseases; Polyradiculoneuropathy; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	詳細
C1 esterase inhibitor (Chengdu Institute of Biological Products)		Phase 1 Clinical	Chengdu Institute Of Biological Products Co Ltd	Angioedemas, Hereditary	詳細

市販薬剤に関する情報

英語名	研究コード	研究開発ステージ	会社	オリジナル製品名	最初に承認をした国	最初の適応症	最初に承認を受けた会社	承認された日付	適応症	臨床試験
Conestat alfa	rhC1-INH	Approved	Pharming Group Nv	Rhucin, Esterasine, Ruconest	EU	Angioedemas, Hereditary	Pharming Group Nv	2010-10-28	Angioedema; Angioedemas, Hereditary; Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Fatigue Syndrome, Chronic; Genetic Diseases, Inborn; Graft Rejection; Non-ST Elevated Myocardial Infarction; Rejection of renal transplantation; Renal Insufficiency	詳細
Sutimlimab	BIVV-009; TNT-009	Approved	True North Therapeutics	ENJAYMO	United States	Anemia, Hemolytic, Autoimmune	Recordati Rare Diseases Inc	2022-02-04	Anemia, Hemolytic, Autoimmune; Clostridium Infections; Hemolysis; Kidney Failure, Chronic; Pemphigoid, Bullous; Purpura, Thrombocytopenic, Idiopathic	詳細
Complement C1 inhibitor protein (Shire ViroPharma)	C1 INH-nf; C1-INH; SHP-616	Approved	Sanquin Plasma Products Bv	Cinryze, Cetor	United States	Angioedemas, Hereditary	null	2008-10-10	Angioedemas, Hereditary; Brain Injuries, Traumatic; Graft Rejection; Rejection of organ transplantation	詳細
C1 esterase inhibitor (Human, CSL Behring)	BI-3.012; CSL-830; CSL-842; CE-1145	Approved	Csl Behring Llc	Berinert, Haegarda, Berinert 2000	Japan	Angioedemas, Hereditary	Csl Behring Llc	1990-06-29	Angioedemas, Hereditary; Hereditary Angioedema Types I and II; Rejection of renal transplantation	詳細